Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Things always take longer than expected, and nothing ever is a sure thing (in trials, in life), but this Seeking Alpha article (from 2013) kind of speaks to where we're at as to validating Kevetrin's potential.... Becoming more a reality than hope.

"As Pfizer Eyes It, Celgene Calls Cellceutix" (Seeking Alpha, May 2013)
http://m.seekingalpha.com/article/1473151-as-pfizer-eyes-it-celgene-calls-cellceutix

EXCERPT
Observers should bear in mind that as Kevetrin advances to maximum tolerable dosage in FDA stage 1, Bologna's hematological trial should begin as an advanced 1b or perhaps a stage 2 trial. Celgene should be concerned this will position Kevetrin into a conspicuous comparison with Celgene's AVL 292. At the sequel of FDA 1, if Kevetrin is awarded "breakthrough" fast track FDA status, pressure will not only be upon Celgene/Avila but also numerous other companies with oncolytic compounds that simply do not hold the triple promise of safety, efficacy, and broad therapeutic index that Kevetrin appears to offer. In such a scenario, Kevetrin as a "breakthrough" compound for P53 activation will probably become and reign for some time as the centripetal force for oncolytic compound conjugation. Concomitantly, Kevetrin will become a primary preemptive weapon against the woeful concern of metastases, as it will provide an immune system defense against the spread of the same cancer throughout other parts of the human body. Where the expectancy of the onset of cancer can be linked to the probability of contribution from P53 dysfunction, then Kevetrin as a non toxic form of chemotherapy might play an important part in perhaps successful early intervention. The aforementioned are all logical outcomes for the pharmaceutical compound that wins the P53 race. This I believe will be a major contribution in humankind making the third step forward in the War on Cancer.
[...]
One of the most important values of Kevetrin is its ability to regulate HDAC2 histone deacetylase. This information was shared with the public on January 17, 2012. Kevetrin's patent covers the 30,000 or more potential compounds.
[...]
What do I believe Kevetrin to be worth? It hinges on the 3 near-term facts to be established soon. One, if FDA 1 at Dana Farber is conclusive regarding Kevetrin's non toxicity to the human genome system. Two, if Kevetrin is indicated to measurably advance therapy to a broad variety of cancer types in patients. Three should the FDA also designate Kevetrin as a "Breakthrough Therapy," then I will begin at 15 billion dollars minimum and perhaps 25 billion.

At approximately 100 million shares issued and outstanding, I see Cellceutix moving toward $100.00 a share during 2014. This is based entirely on a joint venture licensing or buyout of Kevetrin. We will probably have some idea of the possibility of these criteria being met after the ASCO meeting in Chicago, in early June, 2013. It appears likely that prior to this year's end that the first two criteria will either be affirmed or become doubtful. The first two affirmed makes the third, most likely. Kevetrin might soon be appropriately proven the "Holy Grail of P53 Therapeutics."

TO THE EFFICACY QUESTION ... Again, we're waiting on more data (IMO, prob won't come til trial finished, and pub'd in a journal), but if the bottom line results reflect what's been stated -- well, then, wowzer.

Check out this study that was pre-released at ASCO tied to a European effort to rank cancer drugs on efficacy -- a push to approve only the most meaningful drugs. Def worth a read.

Overview
http://www.theguardian.com/society/2015/may/29/cancer-drugs-effectiveness-score-esmo-rankings

The PDF below is the actual study.... See pgs 24 on... Criteria they're proposing and data tables of the various approved cancer drugs by condition (lung, breast, prostate, colorectal, ovarian, renal cell, sarcoma, melanoma, pancreatic), how well they would have scored under the proposed scorecard......

Obv if Kevetrin performs as expected (highly efficacious----stabilizing, daresay, "curing" some cancers), then, per this article, it's use would be widespread.

Full Study
http://static.guim.co.uk/ni/1432986420413/Ann-Oncol-2015.pdf